New drug combo targets Tough-to-Treat colorectal cancer in phase 3 trial
NCT ID NCT06008119
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests whether combining two drugs, tunlametinib and vemurafenib, can help people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation). About 165 adults aged 18 to 70 with metastatic disease will receive the combination to see if it slows cancer growth. The goal is to improve control of the cancer, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Oncology Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.